Search

Your search keyword '"Dizman, Nazli"' showing total 348 results
Start Over Author "Dizman, Nazli"
348 results on '"Dizman, Nazli"'

1. Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Author

Ebrahimi, Hedyeh, Dizman, Nazli, Meza, Luis, Malhotra, Jasnoor, Li, Xiaochen, Dorff, Tanya, Frankel, Paul, Llamas-Quitiquit, Marian, Hsu, Joann, Zengin, Zeynep B., Alcantara, Marice, Castro, Daniela, Mercier, Benjamin, Chawla, Neal, Chehrazi-Raffle, Alex, Barragan-Carrillo, Regina, Jaime-Casas, Salvador, Govindarajan, Ameish, Gillece, John, Trent, Jeffrey, Lee, Peter P., Parks, Thomas P., Takahashi, Motomichi, Hayashi, Atsushi, Kortylewski, Marcin, Caporaso, J. Gregory, Lee, Keehoon, Tripathi, Abhishek, and Pal, Sumanta K.

Published
2024
Full Text
View/download PDF

2. Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium.

Author

El Zarif, Talal, Nassar, Amin, Adib, Elio, Fitzgerald, Bailey, Huang, Jiaming, Mouhieddine, Tarek, Rubinstein, Paul, Nonato, Taylor, McKay, Rana, Li, Mingjia, Mittra, Arjun, Owen, Dwight, Baiocchi, Robert, Lorentsen, Michael, Dittus, Christopher, Dizman, Nazli, Falohun, Adewunmi, Abdel-Wahab, Noha, Diab, Adi, Bankapur, Anand, Reed, Alexandra, Kim, Chul, Arora, Aakriti, Shah, Neil, El-Am, Edward, Kozaily, Elie, Abdallah, Wassim, Al-Hader, Ahmad, Abu Ghazal, Batool, Saeed, Anwaar, Drolen, Claire, Lechner, Melissa, Drakaki, Alexandra, Baena, Javier, Nebhan, Caroline, Haykal, Tarek, Morse, Michael, Cortellini, Alessio, Pinato, David, Dalla Pria, Alessia, Hall, Evan, Bakalov, Veli, Bahary, Nathan, Rajkumar, Aarthi, Mangla, Ankit, Shah, Vishal, Singh, Parminder, Aboubakar Nana, Frank, Lopetegui-Lia, Nerea, Dima, Danai, Dobbs, Ryan, Funchain, Pauline, Saleem, Rabia, Woodford, Rachel, Long, Georgina, Menzies, Alexander, Genova, Carlo, Barletta, Giulia, Puri, Sonam, Florou, Vaia, Idossa, Dame, Saponara, Maristella, Queirolo, Paola, Lamberti, Giuseppe, Addeo, Alfredo, Bersanelli, Melissa, Freeman, Dory, Xie, Wanling, Reid, Erin, Chiao, Elizabeth, Sharon, Elad, Johnson, Douglas, Ramaswami, Ramya, Bower, Mark, Emu, Brinda, Marron, Thomas, Choueiri, Toni, Baden, Lindsey, Lurain, Kathryn, Sonpavde, Guru, and Naqash, Abdul

Subjects
Male, Humans, Middle Aged, Female, Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck, Liver Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Head and Neck Neoplasms, HIV Infections
Abstract

PURPOSE: Compared with people living without HIV (PWOH), people living with HIV (PWH) and cancer have traditionally been excluded from immune checkpoint inhibitor (ICI) trials. Furthermore, there is a paucity of real-world data on the use of ICIs in PWH and cancer. METHODS: This retrospective study included PWH treated with anti-PD-1- or anti-PD-L1-based therapies for advanced cancers. Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS). Objective response rates (ORRs) were measured per RECIST 1.1 or other tumor-specific criteria, whenever feasible. Restricted mean survival time (RMST) was used to compare OS and PFS between matched PWH and PWOH with metastatic NSCLC (mNSCLC). RESULTS: Among 390 PWH, median age was 58 years, 85% (n = 331) were males, 36% (n = 138) were Black; 70% (n = 274) received anti-PD-1/anti-PD-L1 monotherapy. Most common cancers were NSCLC (28%, n = 111), hepatocellular carcinoma ([HCC]; 11%, n = 44), and head and neck squamous cell carcinoma (HNSCC; 10%, n = 39). Seventy percent (152/216) had CD4+ T cell counts ≥200 cells/µL, and 94% (179/190) had HIV viral load

Published
2023

3. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research

Author

Ebrahimi, Hedyeh, Castro, Daniela V., Feng, Matthew I., Prajapati, Sweta R., Lee, Kyle O., Chan, Elyse H., Paul, Trishita, Sehgal, Ishaan, Patel, Jalen, Li, Xiaochan, Zengin, Zeynep B., Meza, Luis, Mercier, Benjamin D., Hsu, JoAnn, Govindarajan, Ameish, Chawla, Neal, Dizman, Nazli, Bergerot, Cristiane D., Rock, Adam, Liu, Sandy, Tripathi, Abhishek, Dorff, Tanya, Pal, Sumanta K., and Chehrazi-Raffle, Alexander

Published
2023
Full Text
View/download PDF

4. Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma

Author

Dizman, Nazli, Govindarajan, Ameish, Zengin, Zeynep B., Meza, Luis, Tripathi, Nishita, Sayegh, Nicolas, Castro, Daniela V., Chan, Elyse H., Lee, Kyle O., Prajapati, Sweta, Feng, Matthew, Loo, Vivian, Pace, Makala, O'Brien, Shea, Bailey, Erin, Barragan-Carrillo, Regina, Chehrazi-Raffle, Alex, Hsu, JoAnn, Li, Xiaochen, Agarwal, Neeraj, and Pal, Sumanta K.

Published
2023
Full Text
View/download PDF

5. Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study

Author

Duarte, Cassandra, Hu, Junxiao, Beuselinck, Benoit, Panian, Justine, Weise, Nicole, Dizman, Nazli, Collier, Katharine A., Rathi, Nityam, Li, Haoran, Elias, Roy, Martinez-Chanza, Nieves, Rose, Tracy L., Harshman, Lauren C., Gopalakrishnan, Dharmesh, Vaishampayan, Ulka, Zakharia, Yousef, Narayan, Vivek, Carneiro, Benedito A., Mega, Anthony, Singla, Nirmish, Meguid, Cheryl, George, Saby, Brugarolas, James, Agarwal, Neeraj, Mortazavi, Amir, Pal, Sumanta, McKay, Rana R., and Lam, Elaine T.

Published
2023
Full Text
View/download PDF

9. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Author

Dizman, Nazli, Meza, Luis, Bergerot, Paulo, Alcantara, Marice, Dorff, Tanya, Lyou, Yung, Frankel, Paul, Cui, Yujie, Mira, Valerie, Llamas, Marian, Hsu, Joann, Zengin, Zeynep, Salgia, Nicholas, Salgia, Sabrina, Malhotra, Jasnoor, Chawla, Neal, Chehrazi-Raffle, Alex, Muddasani, Ramya, Gillece, John, Reining, Lauren, Trent, Jeff, Takahashi, Motomichi, Oka, Kentaro, Higashi, Seiya, Kortylewski, Marcin, Highlander, Sarah K., and Pal, Sumanta K.

Published
2022
Full Text
View/download PDF

13. Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy

Author

Ebrahimi, Hedyeh, primary, Battle, Dena, additional, Salgia, Nicholas J., additional, Zengin, Zeynep B., additional, Dizman, Nazli, additional, Meza, Luis, additional, Bergerot, Cristiane D., additional, Barragan-Carrillo, Regina, additional, Hsu, JoAnn, additional, Castro, Daniela, additional, Mercier, Benjamin, additional, Chawla, Neal, additional, Li, Xiaochen, additional, Tripathi, Abhishek, additional, Liu, Sandy T., additional, Chehrazi-Raffle, Alex, additional, Vaishampayan, Ulka, additional, Staehler, Michael D., additional, and Pal, Sumanta K., additional

Published
2024
Full Text
View/download PDF

14. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma

Author

Chehrazi-Raffle, Alexander, Muddasani, Ramya, Dizman, Nazli, Hsu, JoAnn, Meza, Luis, Zengin, Zeynep B., Malhotra, Jasnoor, Chawla, Neal, Dorff, Tanya, Contente-Cuomo, Tania, Dinwiddie, Devin, McDonald, Bradon R., McDaniel, Timothy, Trent, Jeffrey M., Baehner, Frederick L., Murtaza, Muhammed, and Pal, Sumanta K.

Published
2023
Full Text
View/download PDF

15. Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis

Author

Araujo, Daniel V., Wells, J. Connor, Hansen, Aaron R., Dizman, Nazli, Pal, Sumanta K., Beuselinck, Benoit, Donskov, Frede, Gan, Chun L., Yan, Flora, Tran, Ben, Kollmannsberger, Christian K., de Velasco, Guillermo, Yuasa, Takeshi, Reaume, M. Neil, Ernst, D. Scott, Powles, Thomas, Bjarnason, Georg A., Choueiri, Toni K., Heng, Daniel Y.C., and Dudani, Shaan

Published
2021
Full Text
View/download PDF

17. Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy

Author

Alcantara, Marice B., primary, Tang, Wilson S., additional, Wang, Dongfang, additional, Kaniowski, Damian, additional, Kang, Elaine, additional, Dizman, Nazli, additional, Chehrazi-Raffle, Alexander, additional, Meza, Luis, additional, Zengin, Zeynep, additional, Hall, Jeremy, additional, Hsu, JoAnn, additional, Egelston, Colt, additional, Moreira, Dayson, additional, Horsager, Alan, additional, Pal, Sumanta K., additional, and Kortylewski, Marcin, additional

Published
2024
Full Text
View/download PDF

20. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy.

Author

Castro, Daniela V., Prajapati, Sweta R., Feng, Matthew I., Chan, Elyse H., Lee, Kyle O., Paul, Trishita, Sehgal, Ishaan, Patel, Jalen, Li, Xiaochen, Zengin, Zeynep B., Ebrahimi, Hedyeh, Govindarajan, Ameish, Meza, Luis, Mercier, Benjamin D., Chawla, Neal S., Dizman, Nazli, Philip, Errol J., Hsu, JoAnn, Bergerot, Cristiane D., and Chehrazi‐Raffle, Alex

Subjects
RENAL cell carcinoma, HEPATITIS C virus, HEPATITIS B virus, HIV, HIV infections
Abstract

Objectives: To characterise the restrictiveness of eligibility criteria in contemporary renal cell carcinoma (RCC) trials, using recommendations from the American Society of Clinical Oncology (ASCO)‐Friends of Cancer Research (FCR) initiative. Methods: vPhase I–III trials assessing systemic therapies in patients with RCC starting between 30 June 2012 and 30 June 2022 were identified. Eligibility criteria regarding brain metastases, prior or concurrent malignancies, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, and human immunodeficiency virus (HIV) infection were identified and stratified into three groups: exclusion, conditional inclusion, and not reported. Descriptive statistics were used to determine the frequency of eligibility criteria. Fisher's exact test or chi‐square test were used to calculate their associations with certain trial characteristics. Results: A total of 423 RCC trials were initially identified of which 112 (26.5%) had sufficient accessible information. Exclusion of patients with HIV infection, HBV/HCV infection, brain metastases, and prior or concurrent malignancies were reported in 74.1%, 53.6%, 33.0%, and 8.0% of trials, respectively. In the context of HIV and HBV/HCV infection, patients were largely excluded from trials evaluating immunotherapy (94.4% and 77.8%, respectively). In addition, brain metastases were excluded in trials assessing targeted therapy (36.4%), combined therapy (33.3%), and immunotherapy (22.2%). Exclusion of patients with prior or concurrent malignancies was less frequently reported, accounting for 9.1%, 8.3%, and 5.6% targeted therapy, combined therapy and immunotherapy trials, respectively. Conclusion: A substantial proportion of RCC trials utilise restrictive eligibility criteria, excluding patients with fairly prevalent comorbidities. Implementing the ASCO‐FCR recommendations will ensure resulting data are more inclusive and aligned with patient populations in the real‐world. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC)

Author

Ebrahimi, Hedyeh, primary, Lu, Kun-Han, additional, Castro, Daniela V, additional, Mercier, Benjamin D, additional, Dizman, Nazli, additional, Barragan-Carrillo, Regina, additional, Govindarajan, Ameish, additional, Meza, Luis, additional, Chawla, Neal S, additional, Hsu, JoAnn, additional, Chehrazi-Raffle, Alexander, additional, Tripathi, Abhishek, additional, Liu, Sandy, additional, Dorff, Tanya B, additional, Wah Wong, Chi, additional, Pal, Sumanta K, additional, and Zengin, Zeynep B, additional

Published
2023
Full Text
View/download PDF

22. The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

Author

Castro, Daniela, primary, Tripathi, Nishita, additional, Sayegh, Nicolas, additional, Gebrael, Georges, additional, Li, Xiaochen, additional, Meza, Luis, additional, Zengin, Zeynep, additional, Chehrazi-Raffle, Alex, additional, Govindarajan, Ameish, additional, Dizman, Nazli, additional, Ebrahimi, Hedyeh, additional, Chawla, Neal, additional, Mercier, Benjamin, additional, Hsu BS, JoAnn, additional, Shi, Jessica, additional, Philip, Errol, additional, Bergerot, Cristiane, additional, Barragan-Carrillo, Regina, additional, and Pal, Sumanta, additional

Published
2023
Full Text
View/download PDF

23. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles

Author

Govindarajan, Ameish, primary, Salgia, Nicholas J., additional, Li, Haiqing, additional, Castro, Daniela V., additional, Mirzapoiazova, Tamara, additional, Armstrong, Brian, additional, Zhao, Dan, additional, Mercier, Benjamin D., additional, Dizman, Nazli, additional, Chawla, Neal, additional, Zengin, Zeynep, additional, Meza, Luis, additional, Tripathi, Nishita, additional, Sayegh, Nicolas, additional, Chehrazi-Raffle, Alex, additional, Tripathi, Abhishek, additional, and Pal, Sumanta K., additional

Published
2023
Full Text
View/download PDF

24. Assessment of eligibility criteria in renal cell carcinoma trials evaluating systemic therapy

Author

Castro, Daniela V., primary, Prajapati, Sweta R., additional, Feng, Matthew I., additional, Chan, Elyse H., additional, Lee, Kyle O., additional, Paul, Trishita, additional, Sehgal, Ishaan, additional, Patel, Jalen, additional, Li, Xiaochen, additional, Zengin, Zeynep B., additional, Ebrahimi, Hedyeh, additional, Govindarajan, Ameish, additional, Meza, Luis, additional, Mercier, Benjamin D., additional, Chawla, Neal S., additional, Dizman, Nazli, additional, Philip, Errol J., additional, Hsu, JoAnn, additional, Bergerot, Cristiane D., additional, Chehrazi‐Raffle, Alex, additional, Rock, Adam, additional, Liu, Sandy, additional, Tripathi, Abhishek, additional, Dorff, Tanya B., additional, and Pal, Sumanta K., additional

Published
2023
Full Text
View/download PDF

25. Combination nivolumab and ipilimumab with and without camu camu in first-line treatment of metastatic renal cell carcinoma (mRCC).

Author

Barragan-Carrillo, Regina, Chawla, Neal Shiv, Salgia, Nicholas, Meza, Luis A, Zengin, Zeynep Busra, Li, Xiaochen, Dizman, Nazli, Ebrahimi, Hedyeh, Hsu, Joann, Castro, Daniela V., Mercier, Benjamin D., Dorff, Tanya B., Tripathi, Abhishek, Bergerot, Cristiane Decat, Bergerot, Paulo Gustavo, Chehrazi-Raffle, Alex, and Pal, Sumanta Kumar

Published
2024
Full Text
View/download PDF

26. Adherence to American Society of Clinical Oncology (ASCO) language of respect (LoR) guidelines in ASCO Annual Meeting prostate cancer (PCa) abstracts.

Author

Barragan-Carrillo, Regina, Wong, Megan Hoikei, Dizman, Nazli, Castro, Daniela V., Mercier, Benjamin D., Li, Xiaochen, Faridi, Amber, Goud, Jaya, Paul, Trishita, Chan, Ethan, Dukkipati, Akasha, Paul, Teebro, Zugman, Miguel, Ebrahimi, Hedyeh, Dorff, Tanya B., Chehrazi-Raffle, Alex, Pal, Sumanta Kumar, Florez, Narjust, and Prowell, Tatiana Michelle

Published
2024
Full Text
View/download PDF

27. Clinical and molecular characterization of urothelial (UC) vs. small cell carcinoma (SCC) of the urinary tract.

Author

Chawla, Neal Shiv, Mercier, Benjamin D., Govindarajan, Ameish, Li, Xiaochen, Castro, Daniela V., Ebrahimi, Hedyeh, Barragan-Carrillo, Regina, Zang, Peter D., LeVee, Alexis Ann, Dizman, Nazli, Hsu, Joann, Meza, Luis A, Zengin, Zeynep Busra, Salgia, Nicholas, Chehrazi-Raffle, Alex, Dorff, Tanya B., Pal, Sumanta Kumar, and Tripathi, Abhishek

Published
2024
Full Text
View/download PDF

28. Impact of insurance payer status (IS) on practice patterns and overall survival (OS) in patients (pts) with metastatic urothelial carcinoma (mUC).

Author

Mercier, Benjamin D., Tripathi, Nishita, Govindarajan, Ameish, Gebrael, Georges, Narang, Arshit, Li, Xiaochen, Castro, Daniela V., Chehrazi-Raffle, Alex, Dizman, Nazli, Ebrahimi, Hedyeh, Chawla, Neal Shiv, Hsu, Joann, Bergerot, Cristiane Decat, Barragan-Carrillo, Regina, Zengin, Zeynep Busra, Meza, Luis A, Pal, Sumanta Kumar, Agarwal, Neeraj, and Tripathi, Abhishek

Published
2024
Full Text
View/download PDF

29. Adherence to ASCO Language of Respect (LoR) guidelines in urothelial carcinoma (UC) abstracts at the 2023 ASCO Annual Meeting.

Author

Castro, Daniela V., Mercier, Benjamin D., Zugman, Miguel, Li, Xiaochen, Barragan-Carrillo, Regina, Wong, Megan Hoikei, Chan, Ethan, Faridi, Amber, Goud, Jaya, Paul, Trishita, Dukkipati, Akasha, Patel, Jalen, Paul, Teebro, Ebrahimi, Hedyeh, Chawla, Neal Shiv, Chehrazi-Raffle, Alex, Prowell, Tatiana Michelle, Florez, Narjust, Dizman, Nazli, and Pal, Sumanta Kumar

Published
2024
Full Text
View/download PDF

30. Evolution of the functionality of microbial communities in patients with metastatic renal cell carcinoma (mRCC) receiving cabozantinib (cabo)/nivolumab (nivo) with or without CBM588: A randomized clinical trial.

Author

Ebrahimi, Hedyeh, Meza, Luis A, Lee, Keehoon, Malhotra, Jasnoor, Alcantara, Marice, Zengin, Zeynep Busra, Dizman, Nazli, Hsu, Joann, Llamas-Quitiquit, Marian, Castro, Daniela V., Mercier, Benjamin D., Barragan-Carrillo, Regina, Chawla, Neal Shiv, Li, Xiaochen, Liu, Sandy, Chehrazi-Raffle, Alex, Dorff, Tanya B., Frankel, Paul Henry, Tripathi, Abhishek, and Pal, Sumanta Kumar

Published
2024
Full Text
View/download PDF

31. From guidelines to accountability: Examining adherence to ASCO Language of Respect in renal cell carcinoma (RCC) abstracts.

Author

Dizman, Nazli, Castro, Daniela V., Mercier, Benjamin D., Li, Xiaochen, Barragan-Carrillo, Regina, Wong, Megan Hoikei, Chan, Ethan, Dukkipati, Akasha, Paul, Teebro, Faridi, Amber, Patel, Jalen, Goud, Jaya, Paul, Trishita, Zugman, Miguel, Ebrahimi, Hedyeh, Chehrazi-Raffle, Alex, Dorff, Tanya B., Prowell, Tatiana Michelle, Pal, Sumanta Kumar, and Florez, Narjust

Published
2024
Full Text
View/download PDF

32. Association between thymectomy and incidence of renal cell carcinoma (RCC).

Author

Barragan-Carrillo, Regina, Ebrahimi, Hedyeh, Chawla, Neal Shiv, Salgia, Nicholas, Castro, Daniela V., Chehrazi-Raffle, Alex, Dizman, Nazli, Hsu, Joann, Meza, Luis A, Zengin, Zeynep Busra, LeVee, Alexis Ann, Tripathi, Abhishek, Dorff, Tanya B., Bergerot, Cristiane Decat, Bergerot, Paulo Gustavo, Eilber, Karyn, Dallas, Kai, and Pal, Sumanta Kumar

Published
2024
Full Text
View/download PDF

33. Targeting STAT3 in tumora-ssociated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy.

Author

Alcantara, Marice B., Tang, Wilson S., Dongfang Wang, Kaniowski, Damian, Kang, Elaine, Dizman, Nazli, Chehrazi-Raffle, Alexander, Meza, Luis, Zengin, Zeynep, Hall, Jeremy, Hsu, JoAnn, Egelston, Colt, Moreira, Dayson, Horsager, Alan, Pal, Sumanta K., and Kortylewski, Marcin

Subjects
BLADDER cancer, IPILIMUMAB, RENAL cancer, STAT proteins, REGULATORY T cells, IMMUNE checkpoint inhibitors, IMMUNE checkpoint proteins
Abstract

Introduction: Immune checkpoint blockade (ICB) improved clinical outcomes in renal and bladder cancer patients, but the response rates remain limited especially in metastatic disease. While STAT3 transcription factor is well-known master regulator of tumor immune evasion, little is known about the role of STAT3 in the resistance of renal or bladder cancers to immunotherapy. Methods: To better understand immune alterations associated with ICB resistance, we assessed blood biomarkers in renal cancer patients classified as responders or non-responders to first line nivolumab/ipilimumab immunotherapy. Results: We observed that non-responders showed elevated levels of proinflammatory mediators, such as IL-1RA, IL-6, IL-8 and to lesser extent IL-10, which are associated with STAT3 activation and tumor immunosuppression. In addition, we found STAT3 activation primarily in circulating myeloid immune cells such as tolerogenic MDSCs. To assess whether STAT3 inhibition within these cell subsets can promote antitumor immune responses and/or enhance sensitivity to ICB in vivo, we used an original antisense oligonucleotide (ASO) strategy for myeloid-cell selective STAT3 knockdown (CpG-STAT3ASO). Our results in syngeneic models of renal and bladder cancers in mice demonstrated potent antitumor activity of CpG-STAT3ASO alone in contrast to PD1 blockade alone in both models. The CpG-STAT3ASO/anti-PD1 combination improved therapeutic efficacy especially against bladder tumors. Therapeutic efficacy correlated with activation of dendritic cells (DCs) and M1 macrophages in the tumor microenvironment, reduced percentages of regulatory T cells (Tregs) and the expansion of CD8 T cells in both tumor models. Discussion/Conclusion: Our study underscores the potential of using myeloidcell targeted CpG-STAT3 inhibitors for genitourinary cancer therapy to disrupt tolerogenic signaling, restore immune cell activity and sensitivity to immune checkpoint inhibitors and/or T cell-based immunotherapies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma.

Author

Chehrazi-Raffle, Alexander, Leong, Sally, Ali, Sana, Kim, Tane, Melamed, Sam, Li, Xiaochen, Zengin, Zeynep, Meza, Luis, Chawla, Neal, Govindarajan, Ameish, Castro, Daniela, Mercier, Benjamin, Ebrahimi, Hedyeh, Dizman, Nazli, Tripathi, Nishita, Sayegh, Nicolas, Rock, Adam, Yeh, James, Pal, Sumanta K, and Onyshchenko, Mykola

Subjects
RENAL cell carcinoma, PATIENT aftercare, SPECIALTY hospitals, CONFIDENCE intervals, HISPANIC Americans, MULTIVARIATE analysis, HEALTH outcome assessment, METASTASIS, IPILIMUMAB, RETROSPECTIVE studies, REGRESSION analysis, CANCER patients, CANCER treatment, NIVOLUMAB, SAFETY-net health care providers, KAPLAN-Meier estimator, DESCRIPTIVE statistics, PROGRESSION-free survival, OVERALL survival, PROPORTIONAL hazards models, EVALUATION
Abstract

Background: There are limited data regarding the impact of ethnicity among patients receiving immune checkpoint inhibitors. We evaluated real-world outcomes between Latinx and non-Latinx patients with metastatic renal-cell carcinoma (mRCC) treated with first-line nivolumab/ipilimumab within 2 different healthcare settings. Methods: We performed a retrospective analysis of patients with mRCC who received nivolumab/ipilimumab within the Los Angeles County Department of Health Services (LAC-DHS), a safety-net healthcare system, and the City of Hope Comprehensive Cancer Center (COH), a tertiary oncology center, between January 1, 2015 and December 31, 2021. Progression-free survival (PFS) and overall survival (OS) were determined using the Kaplan-Meier method and covariates were adjusted using multivariate Cox proportional hazards regression. Results: Of 94 patients, 40 patients (43%) were Latinx while the remainder were non-Latinx (44 pts [46%] White, 7 pts [7%] Asian, and 3 pts [3%] Other). Fifty (53%) and 44 (47%) patients received their care at COH and LAC-DHS, respectively. Most Latinx patients (95%) were treated at LAC-DHS, and most non-Latinx patients (89%) were treated at COH. Pooled analysis by ethnicity demonstrated significantly shorter PFS in Latinx versus non-Latinx patients (10.1 vs. 25.2 months, hazard ratios [HR] 3.61, 95% CI 1.96-6.66, P ≤.01). Multivariate analysis revealed a HR of 3.41 (95% CI 1.31-8.84; P =.01). At a median follow-up of 11.0 months, the median OS was not reached in either arm at the time of data cutoff. Conclusion: Latinx patients with mRCC had a shorter PFS treated with frontline nivolumab/ipilimumab compared to their non-Latinx counterparts. No difference was observed in OS although these data were immature. Larger studies are needed to further interrogate the social and economic determinants of ethnicity on clinical outcomes in mRCC. This article evaluates real-world outcomes between Latinx and non-Latinx patients with metastatic renal-cell carcinoma treated with first-line nivolumab/ipilimumab within 2 different healthcare settings. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

35. Race/Ethnicity and Gender Representation in Hematology and Oncology Editorial Boards: What is the State of Diversity?

Author

Patel, Shruti R, primary, Riano, Ivy, additional, Abuali, Inas, additional, Ai, Angela, additional, Geiger, Gabriella, additional, Pimienta, Jacqueline, additional, Ramirez Roggio, Adriana, additional, Dhawan, Natasha, additional, Dizman, Nazli, additional, Lizette Salinas, Alexandra, additional, Pomares-Millan, Hugo, additional, and Florez, Narjust, additional

Published
2023
Full Text
View/download PDF

38. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis.

Author

Meza, Luis, Zengin, Zeynep, Salgia, Sabrina, Malhotra, Jasnoor, Karczewska, Ewa, Dorff, Tanya, Tripathi, Abhishek, Ely, Jennifer, Kelley, Erin, Mead, Heather, Hsu, JoAnn, Dizman, Nazli, Salgia, Nicholas, Chawla, Neal, Chehrazi-Raffle, Alex, Muddasani, Ramya, Govindarajan, Ameish, Rock, Adam, Liu, Sandy, and Salgia, Ravi

Subjects
RENAL cell carcinoma, PATIENT aftercare, IMMUNIZATION, IMMUNOGLOBULINS, CONFIDENCE intervals, COVID-19 vaccines, GENITOURINARY organ tumors, SEROCONVERSION, CANCER patients, T-test (Statistics), IMMUNITY, ENZYME-linked immunosorbent assay, T cells, ODDS ratio, PROSTATE tumors
Abstract

Background: Vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have had a transformative impact on morbidity and mortality. However, the long-term impact of vaccination on patients with genitourinary cancers is currently unknown. Materials and Methods: This study aimed to assess seroconversion rates in patients with genitourinary cancers receiving COVID-19 vaccination. Patients with prostate cancer, renal cell carcinoma, or urothelial cancer who had not been vaccinated for COVID-19 were included. Blood samples were obtained at baseline and after 2, 6, and 12 months of one dose of an FDA-approved COVID-19 vaccine. Antibody titer analysis was performed using the SCoV-2 Detect IgG ELISA assay, and the results were reported as immune status ratio (ISR). A paired t-test was used for comparison of ISR values between timepoints. In addition, T-cell receptor (TCR) sequencing was performed to assess for differences in TCR repertoire 2 months after vaccination. Results: Out of 133 patients enrolled, 98 baseline blood samples were collected. At 2-, 6-, and 12-month time points 98, 70, and 50 samples were collected, respectively. Median age was 67 (IQR, 62-75), with the majority of patients diagnosed with prostate (55.1%) or renal cell carcinoma (41.8%). Compared to baseline (0.24 [95% CI, 0.19-0.31]) a significant increase in the geometric mean ISR values was observed at the 2-month timepoint (5.59 [4.76-6.55]) (P <.001). However, at the 6-month timepoint, a significant decrease in the ISR values was observed (4.66 [95% CI, 4.04-5.38]; P <.0001). Notably, at the 12-month timepoint, the addition of a booster dose resulted in an absolute increase in the ISR values compared to those who did not receive a booster dose (P =.04). Conclusions: Only a minority of patients with genitourinary cancers did not ultimately achieve satisfactory seroconversion after receiving commercial COVID-19 vaccination. Cancer type or treatment rendered did not appear to affect the immune response mounted after vaccination. The long-term effect of vaccination against SARS-CoV-2 on patients with genitourinary cancers is currently unknown. This study assessed the long-term effect of commercially available COVID-19 vaccination in patients with renal cell carcinoma, urothelial carcinoma, and prostate cancer. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. Evaluation of eligibility criteria in contemporary renal cell carcinoma based on ASCO-FCR recommendations.

Author

Prajapati, Sweta R., primary, Feng, Matthew I., additional, Castro, Daniela V., additional, Lee, Kyle O., additional, Chan, Elyse H., additional, Sehgal, Ishaan, additional, Patel, Jalen, additional, O'Dell, Anna, additional, Zengin, Zeynep Busra, additional, Li, Xiaochen, additional, Chehrazi-Raffle, Alex, additional, Dizman, Nazli, additional, Tripathi, Abhishek, additional, Rock, Adam, additional, Liu, Sandy, additional, Mercier, Benjamin D., additional, Meza, Luis A, additional, Philip, Errol James, additional, Dorff, Tanya B., additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

40. Implications of ethnicity among patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (nivo/ipi).

Author

Leong, Sally, primary, Ali, Sana, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Dizman, Nazli, additional, Ebrahimi, Hedyeh, additional, Govindarajan, Ameish, additional, Castro, Daniela V., additional, Li, Xiaochen, additional, Kim, Tane, additional, Melamed, Sam, additional, Onyshchenko, Mykola, additional, Pal, Sumanta Monty, additional, and Chehrazi-Raffle, Alex, additional

Published
2023
Full Text
View/download PDF

41. Impact of race and payer status on the choice of urinary diversion among patients with localized bladder carcinoma undergoing cystectomy.

Author

Tripathi, Abhishek, primary, Barragan-Carrillo, Regina, additional, Philip, Errol James, additional, Govindarajan, Ameish, additional, Chawla, Neal, additional, Castro, Daniela V., additional, Chehrazi-Raffle, Alexander, additional, Dizman, Nazli, additional, Hsu, Joann, additional, Meza, Luis A, additional, Zengin, Zeynep Busra, additional, Bergerot, Cristiane Decat, additional, Eilber, Karyn, additional, Pal, Sumanta Monty, additional, and Dallas, Kai, additional

Published
2023
Full Text
View/download PDF

42. Impact of race and payor status on patterns of utilization of partial and radical nephrectomy in patients with localized renal cell carcinoma (RCC).

Author

Barragan-Carrillo, Regina, primary, Dallas, Kai, additional, Tripathi, Abhishek, additional, Govindarajan, Ameish, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Philip, Errol James, additional, Castro, Daniela V., additional, Chehrazi-Raffle, Alexander, additional, Chawla, Neal, additional, Hsu, Joann, additional, Dizman, Nazli, additional, Eilber, Karyn, additional, Bergerot, Cristiane Decat, additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

43. Association between time-of-day of the immune checkpoint inhibitor (ICI) infusion and disease outcomes among patients with metastatic renal cell carcinoma (mRCC).

Author

Dizman, Nazli, primary, Govindarajan, Ameish, additional, Zengin, Zeynep Busra, additional, Meza, Luis A, additional, Tripathi, Nishita, additional, Sayegh, Nicolas, additional, Castro, Daniela V., additional, Chan, Elyse H., additional, Lee, Kyle O., additional, Prajapati, Sweta R., additional, Feng, Matthew I., additional, Loo, Vivian, additional, Pace, Makala, additional, O'brien, Shea, additional, Bailey, Erin B., additional, Barragan-Carrillo, Regina, additional, Chehrazi-Raffle, Alex, additional, Li, Xiaochen, additional, Agarwal, Neeraj, additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

44. Prevalence of dietary modification and supplement use in patients with metastatic renal cell carcinoma (mRCC).

Author

Ebrahimi, Hedyeh, primary, Battle, Dena, additional, Zengin, Zeynep Busra, additional, Dizman, Nazli, additional, Meza, Luis A, additional, Castro, Daniela V., additional, Govindarajan, Ameish, additional, Mercier, Benjamin D., additional, Chawla, Neal Shiv, additional, Chehrazi-Raffle, Alex, additional, Tripathi, Abhishek, additional, Liu, Sandy, additional, Vaishampayan, Ulka N., additional, Staehler, Michael D., additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

45. Evaluation of eligibility criteria in advanced prostate cancer clinical trials based on ASCO-FCR recommendations.

Author

Feng, Matthew I., primary, Prajapati, Sweta R., additional, Castro, Daniela V., additional, Lee, Kyle O., additional, Chan, Elyse H., additional, Sehgal, Ishaan, additional, Patel, Jalen, additional, O'Dell, Anna, additional, Zengin, Zeynep Busra, additional, Li, Xiaochen, additional, Chehrazi-Raffle, Alex, additional, Dizman, Nazli, additional, Tripathi, Abhishek, additional, Rock, Adam, additional, Liu, Sandy, additional, Mercier, Benjamin D., additional, Meza, Luis A, additional, Philip, Errol James, additional, Dorff, Tanya B., additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

46. Assessment of eligibility criteria in advanced urothelial cancer (aUC) trials based on ASCO-FCR recommendations.

Author

Castro, Daniela V., primary, Feng, Matthew I., additional, Prajapati, Sweta R., additional, Chan, Elyse H., additional, Lee, Kyle O., additional, Sehgal, Ishaan, additional, Patel, Jalen, additional, O'Dell, Anna, additional, Zengin, Zeynep Busra, additional, Li, Xiaochen, additional, Chehrazi-Raffle, Alex, additional, Dizman, Nazli, additional, Tripathi, Abhishek, additional, Rock, Adam, additional, Liu, Sandy, additional, Mercier, Benjamin D., additional, Meza, Luis A, additional, Philip, Errol James, additional, Dorff, Tanya B., additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

47. Genomic and Clinical Prognostic Factors in Patients With Advanced Urothelial Carcinoma Receiving Immune Checkpoint Inhibitors

Author

Chawla, Neal S., primary, Sayegh, Nicolas, additional, Tripathi, Nishita, additional, Govindarajan, Ameish, additional, Zengin, Zeynep B., additional, Phillip, Errol J., additional, Dizman, Nazli, additional, Meza, Luis, additional, Muddasani, Ramya, additional, Chehrazi-Raffle, Alexander, additional, Malhotra, Jasnoor, additional, Hsu, JoAnn, additional, Agarwal, Neeraj, additional, Pal, Sumanta K., additional, and Tripathi, Abhishek, additional

Published
2023
Full Text
View/download PDF

48. Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma

Author

Shayeb, Akram M., primary, McManus, Hannah Dzimitrowicz, additional, Urman, Danielle, additional, Jani, Chinmay, additional, Zhang, Tian, additional, Dizman, Nazli, additional, Meza, Luis, additional, Sivakumar, Akhilesh, additional, Gan, Chun L., additional, Barata, Pedro, additional, Bilen, Mehmet A., additional, Gao, Xin, additional, Heng, Daniel, additional, Pal, Sumanta, additional, Narra, Ravi, additional, Kilari, Deepak, additional, Kaymakcalan, Marina D., additional, McGregor, Bradley, additional, Choueiri, Toni K., additional, and McKay, Rana R., additional

Published
2023
Full Text
View/download PDF

49. Perceptions of COVID-19 Vaccination in Patients with Genitourinary Cancers: A Survey Study

Author

Castro, Daniela V., primary, Zengin, Zeynep B., additional, Malhotra, Jasnoor, additional, Bergerot, Cristiane D., additional, Meza, Luis, additional, Dizman, Nazli, additional, Govindarajan, Ameish, additional, Hsu, JoAnn, additional, Chehrazi-Raffle, Alex, additional, Chawla, Neal, additional, Mercier, Benjamin D., additional, Chen, Sean W., additional, Feng, Matthew, additional, Prajapati, Sweta, additional, Lee, Kyle O., additional, Philip, Errol J., additional, Dorff, Tanya B., additional, Lyou, Yung, additional, and Pal, Sumanta K., additional

Published
2023
Full Text
View/download PDF

50. Genomic and Transcriptomic Predictors of Response from Stereotactic Body Radiation Therapy in Patients with Oligoprogressive Renal Cell Carcinoma

Author

Zengin, Zeynep B., primary, Govindarajan, Ameish, additional, Salgia, Nicholas, additional, Sayegh, Nicolas, additional, Tripathi, Nishita, additional, Muddasani, Ramya, additional, Chehrazi-Raffle, Alex, additional, Feng, Matthew, additional, Mercier, Benjamin D., additional, Ladbury, Colton, additional, Hao, Claire, additional, Salgia, Sabrina, additional, Chawla, Neal, additional, Meza, Luis, additional, Malhotra, Jasnoor, additional, Dizman, Nazli, additional, Hsu, JoAnn, additional, Castro, Daniela V., additional, Barragan-Carrillo, Regina, additional, Ebrahimi, Hedyeh, additional, Philip, Errol J., additional, Chang, Mark, additional, Zhang, Jiaming, additional, Byron, Sara, additional, Lyou, Yung, additional, Dorff, Tanya, additional, Pal, Sumanta K., additional, and Dandapani, Savita, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results